Source: Jastreboff et al., NEJM 2023 TRIUMPH-4 Phase 3 (68 weeks, 445 participants) Phase 2 Type 2 Diabetes Trial (36 weeks, 281 participants) In the type 2 diabetes population, weight loss was lower than in the obesity trial which is consistent with the pattern seen across all GLP-1 drugs
As with most medications, Semaglutide poses a higher risk for people with certain medical conditions, including the following: Medullary thyroid cancer (MTC) Multiple endocrine neoplasia type 2 Pancreatitis Type 1 diabetes Semaglutide should be used cautiously on those already taking medications that lower blood sugar
Novo Nordisk adds that the pill is manufactured end-to-end in the U.S
Shineman DW, Salthouse TA, Launer LJ, et al
It slows down repair, weakens recovery, and makes you feel drained
BPC-157 is not supplied as a licensed medicinal product